Related Experiment Video
Updated: Jul 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin
Marianne Ulcickas Yood1, Bruce D McCarthy, Judy Kempf
1EpiSource, Hamden, CT, USA. muyood@muyood.com
Insights
African Americans are less likely to reach their low-density lipoprotein (LDL) goal when treated with statins compared to whites. This disparity persists even after accounting for adherence and other factors, suggesting potential differences in treatment needs.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Health Disparities
Background:
- African Americans generally have poorer hyperlipidemia control than white individuals.
- Previous research has not examined racial differences in achieving low-density lipoprotein (LDL) goals among treated patients.
Purpose of the Study:
- To investigate the effect of race on achieving target LDL goals in patients initiating statin therapy.
- To compare LDL goal attainment between African American and white patients receiving statins.
Main Methods:
- Retrospective analysis of computerized data from a Midwestern health system.
- Inclusion of adult African American and white patients who filled their first statin prescription between January 1, 1997, and June 30, 2001.
- Follow-up of LDL cholesterol levels for one year post-index prescription.
Main Results:
- A total of 16,052 new statin users were identified, with 32.5% being African American.
- African Americans had higher mean baseline LDL levels (170.2 mg/dL) than whites (161.8 mg/dL).
- Whites demonstrated higher adherence to statin therapy (48.6% vs. 31.2%) and were more likely to reach their LDL goal (71.1% vs. 49.5%).
- Even after adjusting for adherence, income, and other factors, African Americans were significantly less likely to achieve LDL goal (HR 0.60, 95% CI 0.57-0.63).
Conclusions:
- African American patients initiating statin therapy are less likely to achieve their LDL goal compared to white patients.
- This racial disparity in LDL goal attainment is not fully explained by differences in statin adherence or other measured covariates.
- Findings suggest that African Americans may require tailored or alternative pharmacologic management strategies for hyperlipidemia.
Background:
Studies indicate that, overall, African Americans are less likely to achieve control of hyperlipidemia compared with whites. No population-based studies have examined the effect of race on achieving target low-density lipoprotein (LDL) goals among treated individuals.
Methods:
Using computerized encounter and laboratory result data, we identified all African American and white patients in a Midwestern health system filling a statin prescription from January 1, 1997, through June 30, 2001 (index prescription), with no prescriptions filled 1 year before index prescription. We followed LDL results for 1 year after index prescription.
Results:
A total of 16052 new statin users (32.5% African American) were identified. Mean baseline LDL was higher for African Americans (170.2 +/- 36.6) than for whites (161.8 +/- 37.2) (P < .001). Whites were more adherent to therapy, with 48.6% of white patients exposed to statins >80% of follow-up time (31.2% of African Americans) (P < .001). By the end of follow-up, 49.5% of African Americans and 71.1% of whites reached LDL goal. A proportional hazards model adjusting for age, sex, median household income, physician specialty, clinic site, baseline LDL, starting dose, and target LDL indicated that African Americans were less likely to reach goal compared with whites (hazard ratio 0.64, 95% CI 0.61-0.68). Results persisted after controlling for racial differences in statin adherence and LDL testing (hazard ratio 0.60, 95% CI 0.57-0.63).
Conclusions:
African American patients initiating statin therapy are less likely to achieve LDL goal, even after controlling for adherence differences and other factors, suggesting that African Americans may require different pharmacologic management.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...